Jacob van Naarden

Jacob van Naarden

Chief Executive Officer at LOXO ONCOLOGY INC

Net worth: 51 M $ as of 31/10/2026

41 year
Health Technology
Finance
Consumer Services

Profile

Mr. Jacob S.
van Naarden
is a President-Lilly Oncology & Executive VP at Eli Lilly & Co. and a Chief Executive Officer at Loxo Oncology, Inc. He is on the Board of Directors at Delfi Diagnostics, Inc. Mr. van Naarden was previously employed as an Analyst by HealthCor Management LP, an Associate by Aisling Capital LLC, and an Analyst by Goldman Sachs & Co. He received his undergraduate degree from Princeton University.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
25/02/2026 36,270 ( 0% ) 51 M $ 31/10/2026

Jacob van Naarden active positions

CompaniesPositionStart
LOXO ONCOLOGY INC Chief Executive Officer -
ELI LILLY AND COMPANY Corporate Officer/Principal 01/01/2024
Director/Board Member 22/06/2022

Former positions of Jacob van Naarden

CompaniesPositionEnd
Analyst-Equity 01/05/2014
Private Equity Analyst 01/01/2013
Analyst-Equity -
See the detail of Jacob van Naarden's experience

Education of Jacob van Naarden

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

95

1st degree connections

7

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies7

Health Technology

Finance

Finance

Finance

Consumer Services

Health Technology

Health Technology

  1. Stock Market
  2. Insiders
  3. Jacob van Naarden